Breakoutwatch Weekly Summary 08/21/2023

You are receiving this email because you are or were a BreakoutWatch.com subscriber, or have subscribed to our weekly newsletter.
To read this newsletter on the site, click here: Newsletter .

Contents

The newsletter has been absent for a few weeks as I have concentrated on correcting some data problems introduced by a hack of the database. I believe all stock data is now correct and watchlist filters are working again. Next week I depart for 4 weeks on a European vacation but will try to produce this newsletter remotely.

Market Summary

Stocks retreat for third consecutive week

Stocks were broadly lower as sentiment appeared to take a blow from a sharp increase in longer-term bond yields and fears of a sharp slowdown in China (see below). The S&P 500 Index ended the week down 5.15% from its July 26 intraday peak. Growth shares should theoretically suffer the most as rising rates place a greater discount on future earnings, but the Russell 1000 Growth Index held up modestly better than its value counterpart. Small-cap stocks performed the worst. T. Rowe Price traders noted that program trading, technical factors, and thin summer trading volumes may have accentuated the market’s swings. [more...]

Major Index Performance

Dow Jones
Last Close 34463.7
Wk. Gain -1.29 %
Yr. Gain 3.97 %
Trend Down
Dow Jones
S&P 500
Last Close 4399.77
Wk. Gain -0.77 %
Yr. Gain 14.18 %
Trend Down
S&P 500
NASDAQ Comp.
Last Close 13497.6
Wk. Gain -0.7 %
Yr. Gain 27.79 %
Trend Down
NASDAQ Comp.
Russell 2000
Last Close 13497.6
Wk. Gain 612.66 %
Yr. Gain 662.68 %
Trend Down
Russell 2000

Performance by Sector

Sector Wk. Change % Yr. Change % Trend
Consumer Discretionary -1.79 27.44 Down
Consumer Staples -1.8 -0.54 Down
Energy 0.77 3.15 Up
Finance -0.62 -0.28 Down
Health Care -1.28 -1.28 Down
Industrials -1.31 11.32 Down
Technology 0.05 34.39 Down
Materials -0.75 4.38 Down
REIT -2.7 -3.37 Down
Telecom -2.08 30.65 Down
Utilities -0.47 -11.85 Down

Breakouts This Week Still Within 5% of Breakout Price (Limit 20 top C Score)

Watchlist Symbol Company Industry C Score* % Gain
SQZ TS Tenaris S.A. American Dep Gold 83.2 % 0.2 %
CWH BRBR BellRing Brands, Inc. Packaged Foods 79 % 0 %
CWH EQT EQT Corporation Asset Management 77.2 % 0.5 %
SQZ NTNX Nutanix, Inc. Software - Infrastructure 72.4 % 2.3 %
SQZ BLBD Blue Bird Corporation Auto Manufacturers 72 % 0.1 %
SQZ ROST Ross Stores, Inc. Apparel Retail 67.6 % 0.4 %
SQZ ORCL Oracle Corporation Software - Infrastructure 67 % 0.1 %
SQZ CFLT Confluent, Inc. Software - Infrastructure 65.4 % 1 %
SQZ SPB Spectrum Brands Holdings, Inc. Specialty Business Services 63 % 0.2 %
SQZ ETNB 89bio, Inc. Biotechnology 57.5 % 2 %
CWH IDYA IDEAYA Biosciences, Inc. Biotechnology 53.2 % 1.6 %
*C score is our assessment of a Stock's correlation to CAN SLIM principles. It combines a stock's Technical and Fundamental merits and is expressed as a percentage.

Breakdowns within 5% of Breakdown Price

Watchlist Symbol Company Industry C Score* % Loss
SS RDNT RadNet, Inc. 69.5 % -4.2 %
SS ARHS Arhaus, Inc. Home Improvement Retail 68.9 % -2.6 %
SS MDLZ Mondelez International, Inc. Confectioners 68 % -3.6 %
SS SQSP Squarespace, Inc. 67.7 % -1.4 %
SS TWO Two Harbors Investment Co Banks - Global 63.8 % -2.9 %
SS ALOT AstroNova, Inc. Computer Hardware 62 % -0.9 %
SS TOST Toast, Inc. 62 % -1.8 %
SS SPRB Spruce Biosciences, Inc. Biotechnology 58.7 % -1.8 %
SS VPG Vishay Precision Group, Inc. Financial Conglomerates 57 % -4.2 %
SS CASS Cass Information Systems, Inc 54.7 % -1.3 %
SS MGNX MacroGenics, Inc. 52.2 % -1.2 %
SS FET Forum Energy Technologies, Inc. Industrial Distribution 49.7 % -4.8 %
SS SUP Superior Industries International, Inc. 44.4 % -4.9 %
*C score is our assessment of a Stock's correlation to CAN SLIM principles. It combines a stock's Technical and Fundamental merits and is expressed as a percentage.

Cup and Handle Chart of the Week

Aug. 16, 2023 /PRNewswire/ -- IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a precision medicine oncology company committed to the discovery and development of targeted therapeutics, announced the achievement of First-Patient-In for the company-sponsored Phase 2 clinical trial evaluating darovasertib as neoadjuvant and adjuvant therapy in primary uveal melanoma (UM) patients.